Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Hepatocellular Carcinoma
Would you consider ivosidenib for a patient with metastatic cholangiocarcinoma and an IDH1 mutation following progression on gem/cis and FOLFOX?
Does the Child Pugh score factor in your treatment decision, i.e. Child Pugh score C?
Related Questions
How do you choose between Atezolizumab/Bevacizumab (IMbrave 150) versus Durvalumab/Tremelimumab (HIMALAYA) in first-line metastatic hepatocellular cancer?
How do you employ focal therapies in localized hepatocellular carcinoma?
Is the increase in RFS seen with adjuvant atezo/bev in IMbrave050 enough to change practice in resected HCC?
What are your top takeaways in GI Cancers from ASCO 2023?
How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?
How would you approach treating a patient who refuses surgery, but has significant residual disease after chemoradiotherapy for squamous cell carcinoma of the esophagus?
How would you manage a positive margin after APR for a patient who received neoadjuvant CAPOX alone due to previous remote prostate cancer radiation?
Would you offer adjuvant chemotherapy or radiation to a resected MSS T3N0 high-rectal lesion with low anterior resection without pre-op therapy?
What are your top takeaways from ESMO 2023?
In which situations do you omit the 5FU bolus in FOLFOX or FOLFIRI?